[Federal Register Volume 75, Number 88 (Friday, May 7, 2010)]
[Notices]
[Pages 25282-25283]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2010-10864]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


Office of the Director, Office of Biotechnology Activities; 
Notice of a Safety Symposium

    There will be a safety symposium entitled ``Gene-Modified T Cells: 
Challenges in Clinical Trial Design with Novel Receptors.'' The meeting 
will be open to the public, with attendance limited to space available. 
Individuals who plan to attend and need special assistance, such as 
sign language interpretation or other reasonable accommodations, should 
notify the Contact Person listed below in advance of the meeting. For 
further information concerning this meeting contact Ms. Chezelle 
George, Administrative Assistant, Office of Biotechnology Activities, 
Office of the Director, National Institutes of Health, 6705 Rockledge 
Drive, Room 750, Bethesda, MD 20892-7985, 301-496-9838, 
<a href="/cdn-cgi/l/email-protection#b6d1d3d9c4d1d3d5f6dbd7dfda98d8dfde98d1d9c0"><span class="__cf_email__" data-cfemail="c5a2a0aab7a2a0a685a8a4aca9ebabacadeba2aab3">[email protected]</span></a>.

    Name of Committee: Recombinant DNA Advisory Committee.
    Date: June 15, 2010.
    Time: 8 a.m. to 5:30 p.m.
    Agenda: The Office of Biotechnology Activities (OBA) and NIH 
Recombinant DNA Advisory Committee will host a symposium entitled 
``Gene Modified T Cells: Challenges in Clinical Trial Design with 
Novel Receptors'' on June 15, 2010 at the Rockville Hotel and 
Executive Center. Experts will discuss data from trials conducted to 
date, the selection of novel antigen targets, the

[[Page 25283]]

potential risks of off-target effects and clinical trial design 
strategies that can maximize both anti-tumor effect and safety. An 
agenda will be posted to OBA's Web site closer to the meeting date. 
Please check the meeting agenda at http://oba.od.nih.gov/rdna/rdna.html for more information.
    Place: Rockville Hotel and Executive Center, 1750 Rockville 
Pike, Rockville, MD 20892.
    Contact Person: Chezelle George, Administrative Assistant, 
Office of Science Policy, Office of Biotechnology Activities, 
National Institutes of Health, 6705 Rockledge Drive, Suite 750-A1, 
Bethesda, MD 20892, 301-496-9838, <a href="/cdn-cgi/l/email-protection#1f787a706d787a7c5f727e76733171767731787069"><span class="__cf_email__" data-cfemail="1c7b79736e7b797f5c717d757032727574327b736a">[email protected]</span></a>.
    Any interested person may file written comments with the panel 
by forwarding the statement to the Contact Person listed on this 
notice. The statement should include the name, address, telephone 
number and when applicable, the business or professional affiliation 
of the interested person. Background information may be obtained by 
contacting NIH OBA by e-mail <a href="/cdn-cgi/l/email-protection#2649444766494208484f4e08414950"><span class="__cf_email__" data-cfemail="9df2fffcddf2f9b3f3f4f5b3faf2eb">[email protected]</span></a>

    Dated: April 29, 2010.
Jacqueline Corrigan-Curay,
Acting Director, Office of Biotechnology Activities, National 
Institutes of Health.
[FR Doc. 2010-10864 Filed 5-6-10; 8:45 am]
BILLING CODE 4140-01-P


</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>